Our sister site, Drug Delivery Business News, reports today that the FDA cleared Tandem’s Control-IQ+ automated insulin delivery algorithm for people with type 2 diabetes.
Control IQ+ builds on the company’s proven Control-IQ algorithm. It also includes enhancements to accommodate input of expanded weight and total daily insulin ranges. Tandem expects to make Control IQ+ available for new and existing customers in the U.S. in March 2025.
San Diego-based Tandem now joins Insulet in offering AID technology for the type 2 population. Medtronic plans to file with the FDA to expand its AID technology to type 2 later this year as well.
Get the full story at our sister site, Drug Delivery Business News.
